Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Published:2015-05-15 Issue:12 Volume:56 Page:3320-3328
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Niesvizky Ruben,Badros Ashraf Z.,Costa Luciano J.,Ely Scott A.,Singhal Seema B.,Stadtmauer Edward A.,Haideri Nisreen A.,Yacoub Abdulraheem,Hess Georg,Lentzsch Suzanne,Spicka Ivan,Chanan-Khan Asher A.,Raab Marc S.,Tarantolo Stefano,Vij Ravi,Zonder Jeffrey A.,Huang Xiangao,Jayabalan David,Di Liberto Maurizio,Huang Xin,Jiang Yuqiu,Kim Sindy T.,Randolph Sophia,Chen-Kiang Selina

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1030641

Reference22 articles.

1. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

2. Immunomodulatory agents changing the landscape of multiple myeloma treatment

3. Current and Emerging Treatment Options for Patients with Relapsed Myeloma

4. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma;HemaSphere;2024-01

2. IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?;Life;2023-11-20

3. Inhibition of USP10 induces myeloma cell apoptosis by promoting cyclin D3 degradation;Acta Pharmacologica Sinica;2023-04-13

4. RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1;Cancer Research;2022-03-15

5. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma;Nature Communications;2022-02-23